4D Molecular Therapeutics (FDMT) Long-Term Investments (2021 - 2026)

4D Molecular Therapeutics (FDMT) has reported Long-Term Investments for 6 consecutive years, with $66.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments fell 51.29% year-over-year to $66.7 million; the TTM figure through Mar 2026 stood at $66.7 million (down 51.29% YoY), while the FY2025 annual figure was $111.4 million, up 38.22% from the prior year.
• Long-Term Investments fell to $66.7 million in Q1 2026 per FDMT's latest filing, from $111.4 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $137.0 million in Q1 2025 and bottomed at $1.4 million in Q1 2023.
• Historically, Long-Term Investments has averaged $55.4 million across 5 years, with a median of $48.8 million in 2024.
• Annual changes were most pronounced in 2023 — Long-Term Investments plunged 97.09% — and 2024, when it soared 4379.86%.
• 4D Molecular Therapeutics' Long-Term Investments stood at $4.9 million in 2022, then soared by 123.19% to $11.0 million in 2023, then jumped by 635.65% to $80.6 million in 2024, then jumped by 38.22% to $111.4 million in 2025, then sank by 40.08% to $66.7 million in 2026.
• Business Quant data shows FDMT's Long-Term Investments at $66.7 million in Q1 2026, $111.4 million in Q4 2025, and $67.2 million in Q3 2025.